SCHEMBL3837596

SCHEMBL3837596

O=C(O)c1sc(-c2ccccc2)nc1CCO

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.58
CDC7 O00311 5/20 0.52
DBF4 Q9UBU7 5/20 0.52
ALDH1A1 P00352 5/20 0.48
MAPT P10636 3/20 0.48
GAA P10253 2/20 0.48
HPGD P15428 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TRPM8 Q7Z2W7 3/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 4/20 0.45
KDM4E B2RXH2 4/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 2/20 0.45
ATM Q13315 1/20 0.45
POLB P06746 2/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MEN1 O00255 1/20 0.44
CCNE1 P24864 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3841307 0.87 TRPM8 (0.47) SMN1; SMN2CDC7DBF4MAPTGAA
SCHEMBL2073067 0.87 RAB9A (0.61) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL12154280 0.87 RAB9A (0.64) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL3837371 0.85 KMT2A (0.54) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL2073958 0.84 PTGDR2 (0.52) SMN1; SMN2ALDH1A1MAPTGAAHPGD
SCHEMBL3841396 0.83 ALDH1A1 (0.52) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL16702679 0.83 SMN1; SMN2 (0.64) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL27500256 0.79 SMN1; SMN2 (0.59) SMN1; SMN2CDC7DBF4ALDH1A1MAPT
SCHEMBL1436076 0.78 RARA (0.50) SMN1; SMN2ALDH1A1MAPTGAA
SCHEMBL6603353 0.75 L3MBTL1 (0.52) ALDH1A1MAPTTRPM8KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101080411-B Thiazolopyridinone derivatives as MCH receptor antagonists LILLY CO ELI 2011-11-02 CN disclosed
EP-1828207-B1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2009-10-28 EP disclosed
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2009-09-17 US disclosed
CN-101080411-A Thiazolopyridinone derivatives as MCH receptor antagonists LILLY CO ELI (US) 2007-11-28 CN disclosed
EP-1828207-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2007-09-05 EP disclosed
WO-2006066174-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233919-A1 THIAZOLOPYRIDINONE DERIVATES AS MCH RECEPTOR ANTAGONISTS MCHR1, MCHR2, MC1R SMN1; SMN2 2461/4885CDC7 4085/4885DBF4 4650/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.